Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

TEL AVIV, Israel, May 02, 2024 – Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotech firm specializing in innovative treatments for fibro-inflammatory diseases, has announced that its CEO, Dr. Adi Mor, will be presenting at the Aegis Virtual Conference on May 7, 2024, at 9:00 am ET. The presentation will be broadcast live online. Registration for the webcast can be accessed via the provided link on the Chemomab website.

Chemomab Therapeutics Ltd., headquartered in Tel Aviv, is focused on developing therapeutic solutions for fibro-inflammatory conditions that currently lack adequate treatment options. Central to Chemomab’s research is the exploration of the role of CCL24 in driving fibrosis and inflammation. This led to the creation of CM-101, a monoclonal antibody designed to neutralize CCL24 activity. Studies conducted both in the lab and with patients suggest that CM-101 is safe and holds promise for treating a range of severe, life-threatening fibro-inflammatory diseases.

To date, Chemomab has shared positive outcomes from three clinical trials involving CM-101. These include a Phase 2a trial targeting liver fibrosis in patients with non-alcoholic steatohepatitis (NASH) and a study initiated by investigators focusing on patients with severe lung injuries. Furthermore, a Phase 2 trial for primary sclerosing cholangitis has finished enrolling participants, with initial results anticipated by mid-2024. Additionally, Chemomab’s CM-101 program aimed at treating systemic sclerosis is ready for Phase 2 trials, supported by an open Investigational New Drug (IND) application in the United States.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!